Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.
- DOI
- 10.1007/s11684-026-1200-8
- Published
- 2026 Jun
- Container
- MedScience
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11684-026-1200-8,
title = {Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.},
author = {Yan Y and Hu X and Sun X and Xiang X and Wang Y and Wang T and Zhang K and Wang L and Jia Y and Gui C and Yu Y and Lyu R and Xiong W and Deng S and Liu W and Huang L and An G and Qiu L and Yi S and Chinese Workshop of Indolent Lymphomas},
year = {2026},
journal = {MedScience},
doi = {10.1007/s11684-026-1200-8},
url = {https://doi.org/10.1007/s11684-026-1200-8}
}RIS
TY - JOUR TI - Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study. AU - Yan Y AU - Hu X AU - Sun X AU - Xiang X AU - Wang Y AU - Wang T AU - Zhang K AU - Wang L AU - Jia Y AU - Gui C AU - Yu Y AU - Lyu R AU - Xiong W AU - Deng S AU - Liu W AU - Huang L AU - An G AU - Qiu L AU - Yi S AU - Chinese Workshop of Indolent Lymphomas PY - 2026 JO - MedScience DO - 10.1007/s11684-026-1200-8 UR - https://doi.org/10.1007/s11684-026-1200-8 ER -
APA
Y, Y., X, H., X, S., X, X., Y, W., T, W., K, Z., L, W., Y, J., C, G., Y, Y., R, L., W, X., S, D., W, L., L, H., G, A., L, Q., S, Y., & Lymphomas, C. W. O. I. (2026). Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.. MedScience. https://doi.org/10.1007/s11684-026-1200-8
Source records
- pubmed · retrieved 2026-09-26T22:30:18.676Z